Komori
Zeria Pharmaceutical (4559) · InitiativeAdvanced

Review of the Appropriateness of Holding Cross-Shareholdings and Reduction

First written in FY2019. 4 of 5 entries say "Advanced", first in FY2020. Latest entry: FY2026.

5entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2019AdvancedFY2020 – FY20262019: 120192020: 120202021: 020212022: 020222023: 120232024: 120242025: 020252026: 12026
Same theme, other companies
Review of the Rationale for Holding Strategic ShareholdingsA theme 1266 companies write about · 1 as a headwind · 670 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 1270 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「(Issue for which the number of shares decreased during the fiscal year) Shares other than unlisted shares: 1 issue. Total sale proceeds relating to the decrease in the number of shares (¥ thousand): 174,000」

    With respect to policy-held shareholdings, the company sold 1 issue during the fiscal year for ¥174 million. There were no issues for which the number of shares increased during the fiscal year.
  2. FY2024AdvancedAnnual report

    「(Issue for which the number of shares decreased during the fiscal year) Shares other than unlisted shares: 1 issue. Total sale proceeds relating to the decrease in the number of shares: ¥2.018804 billion」

    With respect to policy-held shareholdings, the company sold 1 issue during the fiscal year, generating sale proceeds of ¥2.018804 billion.
  3. FY2023AdvancedAnnual report

    「(Issues for which the number of shares increased during the fiscal year) Shares other than unlisted shares: 4 issues. Total acquisition cost relating to the increase in the number of shares: ¥157.718 million (Issues for which the number of shares decreased during the fiscal year) Shares other than unlisted shares: 1 issue. Total sale proceeds relating to the decrease in the number of shares: ¥212.908 million」

    The company continued to review its policy-held shareholdings. During the fiscal year, the number of shares increased for 4 issues, and 1 issue was sold.
  4. FY2020AdvancedAnnual report

    「For each policy-held shareholding, the company also scrutinises the purpose of holding the shares and the profitability of the shareholding at meetings of the Board of Directors and the full-time officers' meeting delegated by the Board, and verifies whether the holding is appropriate. For holdings whose significance is not recognised, the company reviews them as appropriate with a view to reducing them.」

    The company continues to review its policy-held shareholdings. During the fiscal year, the number of shares increased for 4 issues, and 3 issues were sold.
  5. FY2019First statedAnnual report

    「For each policy-held shareholding, the company scrutinises the purpose of holding the shares and the profitability of the shareholding at meetings of the Board of Directors and the full-time officers' meeting delegated by the Board, and verifies whether the holding is appropriate. For holdings whose significance is not recognised, the company reviews them as appropriate with a view to reducing them.」

    The company has for the first time described as a policy the practice of verifying the appropriateness of policy-held shareholdings at Board of Directors meetings and other forums, and reducing holdings whose significance is not recognised.
Moved together

"Strengthening the Foundation as a Global Company" moved the same way as this thread, in the same document, in 4 of its 5 moves.

444444★123456
  1. ★This thread
  2. 1Strengthening the Foundation as a Global Company4×
  3. 2Enhancing the New Drug Pipeline and Consumer Healthcare Products4×
  4. 3Progress in Clinical Trials and Regulatory Filings for Multiple Products4×
  5. 4Strengthening the Consumer Healthcare Product Lineup4×
  6. 5Expansion of overseas sales4×
  7. 6Increase in the ratio of overseas sales4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Zeria Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.